Published in Blood on September 01, 2009
How I treat hemophagocytic lymphohistiocytosis. Blood (2011) 5.08
Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood (2010) 2.31
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood (2013) 1.95
Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev (2010) 1.68
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood (2011) 1.55
T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol (2012) 1.36
Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant (2010) 1.04
Comparison of commercial extraction systems and PCR assays for quantification of Epstein-Barr virus DNA load in whole blood. J Clin Microbiol (2012) 0.99
Donor-derived second hematologic malignancies after cord blood transplantation. Biol Blood Marrow Transplant (2010) 0.98
Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica (2013) 0.95
Antiviral T-cell therapy. Immunol Rev (2014) 0.91
Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. Br J Haematol (2014) 0.91
Characterization of EBV-related lymphoproliferative lesions arising in donor lymphocytes of transplanted human tumor tissues in the NOG mouse. Exp Anim (2014) 0.89
Prospective evaluation of epstein-barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy. J Clin Immunol (2010) 0.87
Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant (2011) 0.87
Interleukin-2-inducible T-cell kinase (ITK) deficiency - clinical and molecular aspects. J Clin Immunol (2014) 0.87
Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients. Transplantation (2013) 0.86
Cellular immune therapy for viral infections in transplant patients. Indian J Med Res (2013) 0.86
EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. Bone Marrow Transplant (2013) 0.85
Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation. Immunotherapy (2010) 0.84
Lymphoma Immunotherapy: Current Status. Front Immunol (2015) 0.84
Posttransplant lymphoproliferative disease after pediatric solid organ transplantation. Clin Dev Immunol (2013) 0.83
Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV. Gene Ther (2012) 0.82
Immunotherapy for opportunistic infections: Current status and future perspectives. Virulence (2016) 0.82
Histone methyltransferase and histone methylation in inflammatory T-cell responses. Immunotherapy (2013) 0.81
Accelerating immune reconstitution after hematopoietic stem cell transplantation. Clin Transl Immunology (2014) 0.81
Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplant (2015) 0.81
T-cell-based therapies for malignancy and infection in childhood. Pediatr Clin North Am (2010) 0.80
Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma. Cancer Sci (2014) 0.80
Posttransplant lymphoproliferative disease after lung transplantation. Clin Dev Immunol (2013) 0.80
Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution. Bone Marrow Transplant (2015) 0.79
Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects. Biol Blood Marrow Transplant (2014) 0.79
Immunotherapy for epstein-barr virus-related lymphomas. Mediterr J Hematol Infect Dis (2009) 0.79
Strategy of pre-emptive management of Epstein-Barr virus post-transplant lymphoproliferative disorder after stem cell transplantation: results of European transplant centers survey. Contemp Oncol (Pozn) (2012) 0.79
Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol (2014) 0.78
Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab. Bone Marrow Transplant (2015) 0.78
Tricyclic Benzo[cd]azulenes selectively inhibit activities of Pim kinases and restrict growth of Epstein-Barr virus-transformed cells. PLoS One (2013) 0.78
Post-transplantation lymphoproliferative disorder in living-donor liver transplantation: a single-center experience. Surg Today (2012) 0.77
Supportive care in patients with acute leukaemia: historical perspectives. Blood Transfus (2014) 0.76
Inhibition of breast cancer cell proliferation through disturbance of the calcineurin/NFAT pathway by human herpesvirus 6B U54 tegument protein. J Virol (2014) 0.76
Epstein-barr virus related lymphoproliferations after stem cell transplantation. Mediterr J Hematol Infect Dis (2009) 0.76
Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget (2015) 0.76
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica (2016) 0.76
The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development. Cancer Immunol Res (2015) 0.76
Epstein-Barr-Virus-Positive B-Cell Lymphoma of Recipient Origin Despite of the Elimination of Clonally EBV-Infected T Cells by Allogeneic Stem Cell Transplantation in a Patient with Chronic Active EBV Infection. Case Rep Transplant (2012) 0.75
Successful treatment of polymorphic post-transplant lymphoproliferative disorder after allo-HSCT with reduction of immunosuppression. Int J Clin Exp Med (2014) 0.75
Summit on cell therapy for cancer: The importance of the interaction of multiple disciplines to advance clinical therapy. J Transl Med (2011) 0.75
T-cell therapy for viral infections following transplantation: why stop at three viruses? Mol Ther (2012) 0.75
Human immunity against EBV-lessons from the clinic. J Exp Med (2017) 0.75
Donor-Derived Smoldering Multiple Myeloma following a Hematopoietic Cell Transplantation for AML. Case Rep Hematol (2017) 0.75
Croup as Unusual Presentation of Post-transplantation Lymphoproliferative Disorder after Liver Transplantation in an 18-month-old Child. Int J Organ Transplant Med (2016) 0.75
Targeting Epstein-Barr virus-transformed B lymphoblastoid cells using antibodies with T-cell receptor-like specificities. Blood (2016) 0.75
Performance of the Real-Q EBV Quantification Kit for Epstein-Barr Virus DNA Quantification in Whole Blood. Ann Lab Med (2017) 0.75
Identification of IG-clonality status as a pre-treatment predictor for mortality in patients with immunodeficiency-associated Epstein-Barr virus-related lymphoproliferative disorders. Haematologica (2014) 0.75
Epstein-Barr virus: general factors, virus-related diseases and measurement of viral load after transplant. Rev Bras Hematol Hemoter (2011) 0.75
Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT. Bone Marrow Transplant (2016) 0.75
The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis. Eur J Pediatr (2013) 0.75
Monomorphic Post-transplant Lymphoproliferative Disorder After Kidney Transplantation and Hematopoietic Stem Cell Transplantation: Clinicopathological Characteristics, Treatments and Prognostic Factors. Indian J Hematol Blood Transfus (2017) 0.75
Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature (1985) 14.39
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood (1998) 6.26
Epstein-Barr virus infection. N Engl J Med (2000) 5.93
Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med (2004) 5.61
Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med (1998) 5.33
Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol (2007) 4.14
Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med (1996) 4.07
Post-transplant lymphoproliferative disorders. Annu Rev Med (2005) 2.82
Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood (2007) 2.61
Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med (1999) 2.27
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood (2005) 1.99
Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A (1999) 1.82
Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant (2008) 1.78
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood (2006) 1.75
Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation (1999) 1.70
Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants. Immunol Res (2007) 1.68
Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis (2006) 1.59
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood (2006) 1.57
Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood (2004) 1.57
Donor T cells to treat EBV-associated lymphoma. N Engl J Med (1994) 1.53
Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res (2002) 1.53
Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation (2001) 1.53
The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther (2007) 1.40
Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant (2007) 1.39
Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med (2001) 1.38
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood (2000) 1.37
Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant (2005) 1.36
Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev (1997) 1.32
Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer (2005) 1.29
Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant (2005) 1.26
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood (2002) 1.22
CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica (2007) 1.20
Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation (1997) 1.19
Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol (1995) 1.19
Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc (2005) 1.17
Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. Blood (2000) 1.16
Posttransplant primary CNS lymphoma. Neuro Oncol (2000) 1.16
Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation (2002) 1.15
Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant (2005) 1.13
Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation (2002) 1.12
Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results Cancer Res (2002) 1.01
Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation (2007) 0.98
Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol (2007) 0.97
Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children. Br J Haematol (2008) 0.95
Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation (2008) 0.95
An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma. Bone Marrow Transplant (2004) 0.92
Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol (2005) 0.92
Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet (2000) 0.91
Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant (2006) 0.89
Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int (2003) 0.87
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma. Pediatr Blood Cancer (2008) 0.87
Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients. Transplantation (2007) 0.86
Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant (2003) 0.86
EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma (2007) 0.86
Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation (2004) 0.82
The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol (2005) 0.81
Rituximab for PTLD of the CNS: is it a 'no-brainer'? Onkologie (2008) 0.81
T cell immunotherapeutic populations control viral infections in bone marrow transplant recipients. Immunol Res (2001) 0.78
Epstein-Barr infection after bone marrow transplantation. Blood (1994) 0.78